Annual long term liabilities:
$465.25M-$141.63M(-23.34%)Summary
- As of today (July 1, 2025), PCRX annual total long term liabilities is $465.25 million, with the most recent change of -$141.63 million (-23.34%) on December 31, 2024.
- During the last 3 years, PCRX annual long term liabilities has fallen by -$358.58 million (-43.53%).
- PCRX annual long term liabilities is now -43.53% below its all-time high of $823.83 million, reached on December 31, 2021.
Performance
PCRX Long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly long term liabilities:
$473.40M+$8.15M(+1.75%)Summary
- As of today (July 1, 2025), PCRX quarterly total long term liabilities is $473.40 million, with the most recent change of +$8.15 million (+1.75%) on March 31, 2025.
- Over the past year, PCRX quarterly long term liabilities has dropped by -$124.32 million (-20.80%).
- PCRX quarterly long term liabilities is now -46.01% below its all-time high of $876.83 million, reached on March 31, 2022.
Performance
PCRX quarterly long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Long term liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
PCRX Long term liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -23.3% | -20.8% |
3 y3 years | -43.5% | -46.0% |
5 y5 years | +26.3% | +29.0% |
PCRX Long term liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -43.5% | at low | -43.9% | +1.8% |
5 y | 5-year | -43.5% | +26.3% | -46.0% | +17.9% |
alltime | all time | -43.5% | +6919.4% | -46.0% | +7408.3% |
PCRX Long term liabilities History
Date | Annual | Quarterly |
---|---|---|
Mar 2025 | - | $473.40M(+1.8%) |
Dec 2024 | $465.25M(-23.3%) | $465.25M(-0.1%) |
Sep 2024 | - | $465.71M(-31.0%) |
Jun 2024 | - | $674.85M(+12.9%) |
Mar 2024 | - | $597.72M(-1.5%) |
Dec 2023 | $606.87M(-20.0%) | $606.87M(-0.4%) |
Sep 2023 | - | $609.25M(-2.6%) |
Jun 2023 | - | $625.49M(-4.7%) |
Mar 2023 | - | $656.68M(-13.4%) |
Dec 2022 | $758.42M(-7.9%) | $758.42M(-8.9%) |
Sep 2022 | - | $832.72M(-1.4%) |
Jun 2022 | - | $844.17M(-3.7%) |
Mar 2022 | - | $876.83M(+6.4%) |
Dec 2021 | $823.83M(+105.2%) | $823.83M(+100.1%) |
Sep 2021 | - | $411.61M(+0.4%) |
Jun 2021 | - | $409.97M(+1.3%) |
Mar 2021 | - | $404.65M(+0.8%) |
Dec 2020 | $401.50M(+9.0%) | $401.50M(-26.9%) |
Sep 2020 | - | $549.31M(+34.8%) |
Jun 2020 | - | $407.38M(+11.0%) |
Mar 2020 | - | $367.03M(-0.4%) |
Dec 2019 | $368.45M(+19.8%) | $368.45M(+0.8%) |
Sep 2019 | - | $365.49M(+0.6%) |
Jun 2019 | - | $363.19M(+9.2%) |
Mar 2019 | - | $332.65M(+8.2%) |
Dec 2018 | $307.47M(+5.1%) | $307.47M(+1.4%) |
Sep 2018 | - | $303.26M(+1.4%) |
Jun 2018 | - | $299.14M(+1.4%) |
Mar 2018 | - | $295.15M(+0.8%) |
Dec 2017 | $292.67M | $292.67M(+1.3%) |
Sep 2017 | - | $288.95M(+0.6%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2017 | - | $287.19M(+1.2%) |
Mar 2017 | - | $283.68M(+122.2%) |
Dec 2016 | $127.65M(+552.8%) | $127.65M(+532.8%) |
Sep 2016 | - | $20.17M(-7.9%) |
Jun 2016 | - | $21.91M(+15.9%) |
Mar 2016 | - | $18.90M(-3.4%) |
Dec 2015 | $19.55M(+31.1%) | $19.55M(+34.3%) |
Sep 2015 | - | $14.56M(+2.3%) |
Jun 2015 | - | $14.24M(-2.2%) |
Mar 2015 | - | $14.56M(-2.4%) |
Dec 2014 | $14.92M(+125.1%) | $14.92M(-1.2%) |
Sep 2014 | - | $15.10M(+3.4%) |
Jun 2014 | - | $14.61M(+128.4%) |
Mar 2014 | - | $6.39M(-3.5%) |
Dec 2013 | $6.63M(-79.3%) | $6.63M(+5.1%) |
Sep 2013 | - | $6.30M(-93.9%) |
Jun 2013 | - | $103.45M(+0.7%) |
Mar 2013 | - | $102.75M(+220.7%) |
Dec 2012 | $32.04M(-3.8%) | $32.04M(-1.6%) |
Sep 2012 | - | $32.55M(-1.7%) |
Jun 2012 | - | $33.11M(-12.6%) |
Mar 2012 | - | $37.86M(+13.7%) |
Dec 2011 | $33.31M(-66.2%) | $33.31M(-27.4%) |
Sep 2011 | - | $45.91M(-1.7%) |
Jun 2011 | - | $46.68M(-0.8%) |
Mar 2011 | - | $47.06M(-52.3%) |
Dec 2010 | $98.62M(+87.9%) | $98.62M(+20.3%) |
Sep 2010 | - | $81.99M(+16.6%) |
Jun 2010 | - | $70.33M(+34.0%) |
Dec 2009 | $52.49M(+101.6%) | $52.49M |
Dec 2008 | $26.04M | - |
FAQ
- What is Pacira BioSciences annual total long term liabilities?
- What is the all time high annual long term liabilities for Pacira BioSciences?
- What is Pacira BioSciences annual long term liabilities year-on-year change?
- What is Pacira BioSciences quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Pacira BioSciences?
- What is Pacira BioSciences quarterly long term liabilities year-on-year change?
What is Pacira BioSciences annual total long term liabilities?
The current annual long term liabilities of PCRX is $465.25M
What is the all time high annual long term liabilities for Pacira BioSciences?
Pacira BioSciences all-time high annual total long term liabilities is $823.83M
What is Pacira BioSciences annual long term liabilities year-on-year change?
Over the past year, PCRX annual total long term liabilities has changed by -$141.63M (-23.34%)
What is Pacira BioSciences quarterly total long term liabilities?
The current quarterly long term liabilities of PCRX is $473.40M
What is the all time high quarterly long term liabilities for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total long term liabilities is $876.83M
What is Pacira BioSciences quarterly long term liabilities year-on-year change?
Over the past year, PCRX quarterly total long term liabilities has changed by -$124.32M (-20.80%)